RxDoctor Payments Data

Jonathan Martin, DO

Infectious Disease · Chicago, ILNPI 1902172083

Payments from drug & device makers

$1,450in general payments, 2019–2025

Across 55 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$736
  • Viiv Healthcare Company$330
  • Merck$123
  • Johnson & Johnson$106
  • Janssen Scientific Affairs, LLC$43
  • Dynavax Technologies Corporation$35
  • plus $77 from 3 others

What the payments were for

  • Speaking & faculty fees$191%
  • Food & beverage$1,43199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,450 in reported general payments places this provider in the 70th percentile of 368 infectious disease providers in Illinois.

See all infectious disease providers in Illinois

Medicare billing

Part B allowed, 2024
$5,917
Medicare patients
33
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala246$980,515
TriumeqAbacavir/Dolutegravir/Lamivudi36$155,020
CabenuvaCabotegravir/Rilpivirine22$152,689
TivicayDolutegravir Sodium59$141,607
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf22$118,833
GenvoyaElviteg/Cob/Emtri/Tenof Alafen23$91,965
DescovyEmtricitabine/Tenofov Alafenam36$78,985
DovatoDolutegravir Sodium/Lamivudine13$41,762
Darunavir35$32,365
PifeltroDoravirine15$26,096
IsentressRaltegravir Potassium12$24,019
XareltoRivaroxaban25$18,927
TrulicityDulaglutide15$13,648
Etravirine12$13,550
EntrestoSacubitril/Valsartan13$13,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$736$1,151,465305 claims
Viiv Healthcare CompanyTriumeq, Cabenuva, Tivicay, Dovato$330$491,078130 claims
MerckPifeltro, Isentress$123$50,11527 claims
Johnson & JohnsonXarelto$106$18,92725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 368 infectious disease providers in Illinois.

Other infectious disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →